CN104473989A - Traditional Chinese medicine tablet for preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof - Google Patents
Traditional Chinese medicine tablet for preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof Download PDFInfo
- Publication number
- CN104473989A CN104473989A CN201410691999.9A CN201410691999A CN104473989A CN 104473989 A CN104473989 A CN 104473989A CN 201410691999 A CN201410691999 A CN 201410691999A CN 104473989 A CN104473989 A CN 104473989A
- Authority
- CN
- China
- Prior art keywords
- chinese medicinal
- active ingredient
- tablet
- cardiovascular
- medicinal tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 23
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 22
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000000843 powder Substances 0.000 claims abstract description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000000284 extract Substances 0.000 claims abstract description 15
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 13
- 241000208340 Araliaceae Species 0.000 claims abstract description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 11
- 235000008434 ginseng Nutrition 0.000 claims abstract description 11
- 239000008187 granular material Substances 0.000 claims abstract description 9
- 239000000314 lubricant Substances 0.000 claims abstract description 9
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 7
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 7
- 238000005507 spraying Methods 0.000 claims abstract description 7
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims abstract description 4
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims abstract description 4
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims abstract description 4
- 239000000080 wetting agent Substances 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 241000628997 Flos Species 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 8
- 239000000945 filler Substances 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 239000012752 auxiliary agent Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- BAHUBXAYVOCLNA-UHFFFAOYSA-N Isoangelol Natural products O1C(=O)C=CC2=C1C=C(OC)C(C(OC(=O)C(C)=CC)C(O)C(C)(C)O)=C2 BAHUBXAYVOCLNA-UHFFFAOYSA-N 0.000 claims description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 4
- 229920003081 Povidone K 30 Polymers 0.000 claims description 4
- 229930183733 angelol Natural products 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 238000004132 cross linking Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 244000124209 Crocus sativus Species 0.000 claims description 3
- 235000015655 Crocus sativus Nutrition 0.000 claims description 3
- 229920001651 Cyanoacrylate Polymers 0.000 claims description 3
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 238000007598 dipping method Methods 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 229920001568 phenolic resin Polymers 0.000 claims description 3
- 239000005011 phenolic resin Substances 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000004248 saffron Substances 0.000 claims description 3
- 235000013974 saffron Nutrition 0.000 claims description 3
- 206010008132 Cerebral thrombosis Diseases 0.000 claims description 2
- 102000009123 Fibrin Human genes 0.000 claims description 2
- 108010073385 Fibrin Proteins 0.000 claims description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- 239000004411 aluminium Substances 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 229950003499 fibrin Drugs 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 abstract description 2
- 238000000034 method Methods 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 6
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 4
- 229940116229 borneol Drugs 0.000 abstract 4
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 4
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 4
- 241000382455 Angelica sinensis Species 0.000 abstract 2
- 244000020518 Carthamus tinctorius Species 0.000 abstract 2
- 241000112528 Ligusticum striatum Species 0.000 abstract 2
- 238000001694 spray drying Methods 0.000 abstract 2
- 239000004615 ingredient Substances 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- 238000003304 gavage Methods 0.000 description 8
- 239000009999 naoan Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 210000002385 vertebral artery Anatomy 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- -1 reflux Substances 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 230000004872 arterial blood pressure Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000003727 cerebral blood flow Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 230000002785 anti-thrombosis Effects 0.000 description 3
- 210000001168 carotid artery common Anatomy 0.000 description 3
- 230000000916 dilatatory effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 210000003270 subclavian artery Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000006200 vaporizer Substances 0.000 description 2
- 229920002955 Art silk Polymers 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000440580 Mammaria Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000531807 Psophiidae Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a traditional Chinese medicine tablet for preventing and treating cardiovascular and cerebrovascular diseases. The tablet comprises 50-60 percent of an active ingredient A, 15-25 percent of an active ingredient B, 0.15-0.2 percent of an active ingredient C and auxiliaries, wherein the active ingredient A is prepared by mixing extracts of ligusticum wallichii, angelica sinensis and safflower carthamus in a weight ratio of 0.8:1.0:0.5; the active ingredient B is ginseng crude powder; and the active ingredient C is borneol. The preparation method comprises the following steps: uniformly mixing extracts of ligusticum wallichii, angelica sinensis and safflower carthamus, ginseng powder, borneol and other effective ingredients with silicon dioxide and polyvinylpolypyrrolidone; adding a wetting agent to granulate, and carrying out spray drying; dissolving borneol with a small amount of absolute ethyl alcohol, and spraying the borneol into dry granules; adding a lubricant, uniformly mixing, and tabletting. The traditional Chinese medicine tablet can be used for remarkably reducing the resistance of cerebrovascular vessels, and preventing and treating cardiovascular and cerebrovascular diseases; by adopting 'spray drying, one-step granulating' and other modern processes, the disintegration and dissolution limits of the tablet in stomachs can be improved, and the stability can be improved.
Description
Technical field
The invention belongs to medical art, be specifically related to a kind of Chinese medicinal tablet preventing and treating cardiovascular and cerebrovascular disease and preparation method thereof.
Background technology
Cardiovascular and cerebrovascular disease is a kind of serious threat mankind, the particularly commonly encountered diseases of more than 50 years old middle-aged and elderly people health, and the number of cardiovascular and cerebrovascular disease is died from every year up to 1,500 ten thousand people in the whole world, occupies the various cause of the death the first.Cardiovascular and cerebrovascular disease has become the highest number one killer of human death's cause of disease, also be health of people " noiseless demon ", the feature that cardiovascular and cerebrovascular disease has " sickness rate is high, disability rate is high, mortality rate is high, relapse rate is high; complication is many " i.e. " four is high by more than one ", at present, China's Patients with Cardiovascular/Cerebrovascular Diseases is more than 2.7 hundred million people, be tending towards rejuvenation in recent years, control cerebrovascular disease, reduce the disability rate caused by this class disease, being state key problem, is also one of medical personnel emphasis problem of jointly tackling key problems.
This type of medicine of foreign market is mainly chemical drugs.Mostly be vasodilation, fall cranium pressing, anti-platelet aggregation agent.On domestic market, existing medicine mainly contains RONGSHUAN JIAONANG, Vitarmin E Nicotinic Acid Capsules, Datang Austria is logical, network is glad leads to.The shortcoming of these medicines be the relative toxic and side effects of partial chemical medicine large, be not suitable for long-term taking; Part herbal species curative effect is not fine; Part kind relative price is higher, and common people's medication is difficult to accept.Existing preparation mainly contains drop pill, capsule etc. in the market.Drop pill extracts, preparation process is complicated, and require high to production equipment, cost is relatively high; The concentrated powder that capsule contains due to capsule 's content, the easily moisture absorption, caking and affect quality in storage transport, and when capsule shells is dissolved under one's belt, local concentration is too high and stimulate gastric mucosa, is unsuitable for some digestive tract ulcer patient.
Summary of the invention
The present invention is directed to the defect that prior art exists, aim to provide a kind of Chinese medicinal tablet preventing and treating cardiovascular and cerebrovascular disease and preparation method thereof.
The present invention realizes especially by following technical scheme:
Prevent and treat a Chinese medicinal tablet for cardiovascular and cerebrovascular disease, comprise 50-60% active components A, 15-25% active component B, 0.15-0.2% active component C and auxiliary agent.
Described active components A is Rhizoma Chuanxiong, the extractum of Radix Angelicae Sinensis Flos Carthami is mixed, and the weight ratio of described Radix Angelicae Sinensis, Rhizoma Chuanxiong Flos Carthami is 0.8:1.0:0.5.
Described active component B is the former powder of Radix Ginseng crude drug.
Described active component C is Borneolum Syntheticum.
Described auxiliary agent is disintegrating agent, filler, binding agent and lubricant, and the percentage composition that each auxiliary agent of normal conditions accounts for Chinese medicinal tablet weight is: disintegrating agent 5-15%, filler 10-25%, binding agent 0.2-0.3%, lubricant 1.5-2.0%.
Described disintegrating agent is one or more in cross-linking sodium carboxymethyl cellulose, dry starch, carboxymethyl starch sodium, polyvinylpolypyrrolidone, low-substituted hydroxypropyl cellulose or silicon dioxide.
Described filler is one or more in silicon dioxide, calcium carbonate, magnesium carbonate, aluminium powder or phenolic resins.
Described binding agent is one or more in PVP K30, starch, cyanoacrylate, fibrin or polyurethane.
Described lubricant is the mixture of Pulvis Talci and magnesium stearate.
Described Chinese medicinal tablet is for preventing and treating the purposes of cardiovascular and cerebrovascular disease, and described cardiovascular and cerebrovascular disease is cerebral thrombosis.
The preparation method of Chinese medicinal tablet of the present invention, specifically comprises the following steps:
1) Rhizoma Chuanxiong, Radix Angelicae Sinensis are rendered to respectively in extraction pot, heat up heating, and reflux, extract, gets supernatant for subsequent use;
2) mixed with the water entering 3 times amount by Flos Carthami, heat up 70 ~ 80 DEG C of hot dipping secondaries after being heated to 100 ~ 105 DEG C, gets supernatant for subsequent use.
3) Rhizoma Chuanxiong, angelol extract merge, and reclaim ethanol, are concentrated into the extractum that relative density is 1.10 (80 DEG C), and after concentrated, extractum adds Radix Ginseng powder, mix homogeneously.
4) Rhizoma Chuanxiong, Radix Angelicae Sinensis, saffron aqueous solution are merged, in vacuum concentration pot, be concentrated into the extractum that relative density is 1.10, let cool, add ethanol and reach 60% to alcohol content, placement is spent the night, the supernatant after leaching precipitate with ethanol, reclaim ethanol, be concentrated into relative density about 1.35 ~ 1.38.
5) by after carrying out pulverizing, sieve operation mix homogeneously after step (3) mixed material and step (4) extract dry, add disintegrating agent, filler, wetting agent granulation, spraying dry, granulate, by Borneolum Syntheticum with spraying in dry granule after a small amount of anhydrous alcohol solution, add mix lubricant evenly after, tabletting.
Beneficial effect of the present invention is: Chinese medicinal tablet of the present invention significantly can reduce cerebral vascular resistance, to the selective dilating effect of cerebrovascular, cerebral blood flow can be increased, improve cerebral circulation, production technology after simultaneously improving has had the raising of matter, whole employing " spraying dry, one-step palletizing " etc. modern crafts, this is while the loss of reduction medicament effective component, avoid the secondary pollution in too many levels is produced, the application of modern crafts and exclusive technique, enhance the curative effect that tablet is stable again, and accomplish that essence is carried refining and reduced dose, alleviate economy and the mental burden of medication, and by overcoming the drawback of concentrated powder moisture absorption caking to the interpolation of label adjuvant and plain coating tablets, substantially increase its disintegrate under one's belt, dissolution limit, add stability, better ensure that medicine inherent quality.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is described further, the following stated, only to preferred embodiment of the present invention, not do other forms of restriction to the present invention, any those skilled in the art may utilize the technology contents of above-mentioned announcement to be changed to the Equivalent embodiments of equal change.Everyly do not depart from the present invention program's content, according to technical spirit of the present invention to any simple modification made for any of the above embodiments or equivalent variations, all drop in protection scope of the present invention.
Application Example one
Embodiment 1
Prevent and treat a Chinese medicinal tablet for cardiovascular and cerebrovascular disease, consist of the following composition: 0.008 gram, the mixture of Radix Angelicae Sinensis 0.106g, Rhizoma Chuanxiong 1.331g, Flos Carthami 0.066g, Radix Ginseng powder 0.10g, Borneolum Syntheticum 0.001g, cross-linking sodium carboxymethyl cellulose 0.005g, silicon dioxide 0.09g, PVP K30 0.014g, Pulvis Talci and magnesium stearate.
The preparation method of this Chinese medicinal tablet is: the section cleaned Rhizoma Chuanxiong, Radix Angelicae Sinensis medical material being cut into 2-3 ㎝, renders in extraction pot after carrying out drying, and heat up heating, timing when seething with excitement from medicinal liquid, reflux, extract, secondary, 2 hours first times, adds 90% alcoholic solution of Chinese crude drug 3 times amount; Second time 1 hour, adds 90% alcoholic solution of Chinese crude drug 2 times amount; Get supernatant, filter respectively, merging filtrate.Medicinal residues add the water of Chinese crude drug 3 times amount, and heat up heating, boils rear beginning timing, decocts secondary, each 1 hour, get supernatant, filter respectively, merging filtrate.Through to clean and load weighted Flos Carthami is put in extraction pot, will add the water of 3 times amount of Chinese crude drug, heat up heating, heating-up time 40-60 minute, reaches boiling (temperature reaches 100 ~ 105 DEG C) 70 ~ 80 DEG C of hot dipping secondaries afterwards, each 2 hours, merge immersion, filter.Rhizoma Chuanxiong, angelol extract merge, and import in single-effect external circulation vaporizer, reclaim ethanol, are concentrated into the extractum that relative density is 1.10 (80 DEG C), and after concentrated, extractum adds Radix Ginseng powder, mix homogeneously.Rhizoma Chuanxiong, Radix Angelicae Sinensis, saffron aqueous solution are merged, imports in vacuum concentration pot, concentrate, be concentrated into the clear paste that relative density is 1.10 (80 DEG C), let cool.Join in settling tank after weighing, add ethanol and reach 60% to alcohol content, stir, the alcohol wash time should be greater than 10 minutes, places and spends the night (12 hours), filters.Supernatant after leaching precipitate with ethanol, imports in single-effect external circulation vaporizer, reclaims ethanol, when being concentrated into relative density about 1.35 ~ 1.38 (60 DEG C), releases.To pulverizing after Rhizoma Chuanxiong, angelol extracted extract and the drying of Radix Ginseng powder's mixed material, operation of sieving; To pulverizing, sieving operation after Rhizoma Chuanxiong, Radix Angelicae Sinensis, Flos Carthami water extract-alcohol precipitation after extract dry, all require 100 mesh sieves, after the two mix homogeneously, obtain active component extract powder.After active component extract powder is mixed homogeneously with cross-linking sodium carboxymethyl cellulose, silicon dioxide, polyvinylpolypyrrolidone with Borneolum Syntheticum, add the alcoholic solution of PVP K30, granulate, spraying dry, granulate, Borneolum Syntheticum is sprayed in dry granule with after a small amount of anhydrous alcohol solution, after adding Pulvis Talci, magnesium stearate mix homogeneously, tabletting.
Embodiment 2
Prevent and treat a Chinese medicinal tablet for cardiovascular and cerebrovascular disease, composed of the following components: 0.03 gram, the mixture of Radix Angelicae Sinensis 0.348g, Rhizoma Chuanxiong 0.435g, Flos Carthami 0.217g, Radix Ginseng powder 0.3g, Borneolum Syntheticum 0.003g, carboxymethyl starch sodium 0.002g, calcium carbonate 0.2g, cyanoacrylate 0.006g, Pulvis Talci and magnesium stearate.
The preparation method of this Chinese medicinal tablet is with embodiment 1.
Embodiment 3
Prevent and treat a Chinese medicinal tablet for cardiovascular and cerebrovascular disease, composed of the following components: 0.023 gram, the mixture of Radix Angelicae Sinensis 0.313g, Rhizoma Chuanxiong 0.391g, Flos Carthami 0.196g, Radix Ginseng powder 0.5g, Borneolum Syntheticum 0.003g, carboxymethyl starch sodium 0.075g, phenolic resins 0.15g, polyurethane 0.003g, Pulvis Talci and magnesium stearate.
The preparation method of this Chinese medicinal tablet is with embodiment 1.
Application Example two
The white mouse experimental vein thrombosis test of embodiment 4 Chinese People's Anti-Japanese Military and Political College
Experimental technique: Wister rat is selected in test
, body weight is 280 ± 15g, laboratory animal is divided into five groups: blank group gavage 2% carboxymethylcellulose sodium solution 3ml/kg; Positive drug NAOAN JIAONANG 300mg/kg; The embodiment of the present invention 1 tablet 30,100 and 300mg/kg; The impartial gavage of injection volume, qd × 7d, at 7d, after gavage medicine 1h, with 3% pentobarbital sodium 45mg/kg intraperitoneal injection of anesthesia, is separated right neck tremulous pulse and left external jugular vein.Get three sections of vinyl tubes, wherein two-stage nitration two internal diameters are 1.5mm, be about 10cm, one, stage casing internal diameter is 2mm, is about 8.5cm, 4 trumpeter's art silk threads that one is about 6.5cm are put in the stage casing of three sections of polyethylene tubes, heparin-saline solution (50 μ l/ml) is full of polyethylene tube intracavity, after left external jugular vein is inserted in one end of plastic tube, the other end of pipe is inserted right common carotid artery, after having performed the operation, open blood flow immediately.Herba Clinopodii in after 15min, takes out rapidly silk thread and weighs, and it is heavily wet weight of thrombus that gross weight deducts line, calculates with mg.
Experimental result: as shown in table 1, embodiment 1 tablet 30mg/kg combines blank group to thrombosis without impact; Embodiment 1 tablet 100 and 300mg/kg group suppression ratio are respectively 39.2% and 47.7%, equal P<0.01, difference is extremely remarkable, illustrates that embodiment 1 tablet 100-300mg/kg has obvious anti thrombotic action, compared with the dosage such as NAOAN JIAONANG, excellent effect.
The impact that table 1 is formed rat suppository
The overall antithrombotic test of embodiment 5 white mice
Test method: get
mice, is divided into five groups at random by test, often organizes 20, blank group gavage 1%CMCNa, 0.5ml/, qd × 10d, embodiment 1 tablet is divided into three groups, is respectively 30,100 and 300mg/kg, equal-volume gavage (0.5ml), qd × 10d, NAOAN JIAONANG 300mg/kg, continuous gavage 10d, after last gavage medicinal liquid, inject thrombosis derivant ADP 480mg/kg by tail vein, after thrombosis derivant injects 15min, visible mice is weak and limp or dead.Be the death toll of each treated animal in this laboratory observation injection ADP 1h, and as Χ2 test, drug effect suppress the percent of mortality rate to represent with it.
Experimental result: as shown in table 2, embodiment 1 tablet gavage 30mg/kg does not have a significant effect (P>0.05) to the mice embolic death that ADP induces; But embodiment 1 tablet 100mg/kg and 300mg/kg suppression ratio reach 39% and 61% (P<0.05) respectively, all have significant difference, compare with NAOAN JIAONANG act on similar.Illustrate that embodiment 1 tablet 100-300mg/kg has obvious antiplatelet aggregative activity, suppress the death that the thromboembolism of ADP induction causes.Compare with NAOAN JIAONANG, effect is similar.
Table 2 is on the impact on the death of mice thrombosis after quiet note ADP
Note: * P<0.05 in table.
Embodiment 6 is on the impact of cerebral vascular resistance
Experimental technique: select 2-3kg healthy rabbits
, 3.5% pentobarbital sodium 35mg/kg intravenous injection anesthesia, is separated right carotid, subclavian artery and vertebral artery, be separated arteria mammaria in also ligation, deep cervical artery, flesh props up, after heparin presses 10mg/kg anticoagulant, make common carotid artery intubate, Bonding pressure transducer, be separated left femoral artery and intubate, another end connects silicon edge sebific duct, after constant speed peristaltic pump, then connects glass T-shaped pipe.Pipe side arm connects another pressure transducer and measures vertebral artery pressure, another termination silica gel tube and polyethylene cannula of pipe, this pipe drives in the wrong direction through subclavian artery and is inserted to vertebral artery opening part, start electronic constant current pump and draw femoral artery blood constant speed perfusion vertebral artery, the proximal part of last ligation subclavian artery and root, common carotid artery pressure (ABP) and vertebral artery pressure (VBP) are all synchronously inputted on eight road life monitors, observation and comparison embodiment 1 tablet is on the impact of cerebral vascular resistance and blood pressure, under insulation (nearly body temperature) condition, constant flow pump is adjusted to make cerebral vascular resistance close with blood pressure (namely align and enter cerebral blood flow close to animal naturalness), after vertebral artery pressure curve stablizes 10min, by imbedding duodenal catheter administration, test medicine and positive drug, blank group administration volume all controls to inject at 0.5ml/kg equal-volume, note fast 5sec, to observe and after recording administration 10, 20, 30, 50, changing value during 60min.
Experimental result: rabbit cerebral vascular resistance test proves, embodiment 1 tablet duodenal administration 1mg/kg, 3mg/kg and 10mg/kg can reduce vertebral artery resistance, difference is extremely remarkable, prove that Tablets can reduce cerebral vascular resistance significantly, increase cerebral blood flow, improve cerebral circulation, compare with NAOAN JIAONANG, act on similar.Specifically in table 3:
Table 3 is on the impact of rabbit cerebral vascular resistance
Note: #P<0.05, ##P<0.01 in table.
The embodiment of the present invention 1 tablet is while reduction cerebral vascular resistance, and human peripheral blood pressure does not almost affect, and illustrates that this medicine is to the selective dilating effect of cerebrovascular, compares with NAOAN JIAONANG, acts on similar, the results are shown in Table 4.
Table 4 is on the impact of rabbits blood pressure
Embodiment 7 virulence experiment
For preventing embodiment 1 tablet from changing after pharmaceutical adjunct, the adjuvant of employing can produce harmful effect to health, has carried out again the acute toxicity test of brain peace sheet, to one in a few days maximum tolerated dose test.Result of the test shows, embodiment 1 tablet gastric infusion maximum tolerated dose is 48g/kg (being equivalent to containing crude drug 23.04g/kg), is equivalent to 1200 times of clinical adult's consumption, does not find that mice has obvious toxic reaction simultaneously in 7 days in the observation period.It can be said that bright Tablets toxicity is lower, for clinical safer.
In sum, Tablets has obvious anti thrombotic action, significantly can reduce cerebral vascular resistance, to the selective dilating effect of cerebrovascular, can cerebral blood flow be increased, improve cerebral circulation, with the dose comparison such as positive drug NAOAN JIAONANG, drug action is similar, illustrates after changing dosage form, any bad impact is not produced on drug effect, also do not reduce the therapeutical effect of medicine.And novel form adds stability and improves quality standard, being easier to store, transport, carry and take, in clinical practice, adding novel form for preventing and treating apoplexy, also for patient medication provides conveniently.
Claims (7)
1. prevent and treat a Chinese medicinal tablet for cardiovascular and cerebrovascular disease, it is characterized in that: comprise 50-60% active components A, 15-25% active component B, 0.15-0.2% active component C and auxiliary agent.
2. Chinese medicinal tablet according to claim 1, is characterized in that:
Described active components A is Rhizoma Chuanxiong, the extractum of Radix Angelicae Sinensis Flos Carthami is mixed, and wherein the weight ratio of Radix Angelicae Sinensis, Rhizoma Chuanxiong Flos Carthami is 0.8:1.0:0.5;
Described active component B is the former powder of Radix Ginseng crude drug;
Described active component C is Borneolum Syntheticum.
3. Chinese medicinal tablet according to claim 1, it is characterized in that: described auxiliary agent is disintegrating agent, filler, binding agent and lubricant, the percentage composition accounting for Chinese medicinal tablet weight is: disintegrating agent 5-15%, filler 10-25%, binding agent 0.2-0.3%, lubricant 1.5-2.0%.
4. Chinese medicinal tablet according to claim 3, is characterized in that:
Described disintegrating agent is one or more in cross-linking sodium carboxymethyl cellulose, dry starch, carboxymethyl starch sodium, polyvinylpolypyrrolidone, low-substituted hydroxypropyl cellulose or silicon dioxide;
Described filler is one or more in silicon dioxide, calcium carbonate, magnesium carbonate, aluminium powder or phenolic resins;
Described binding agent is one or more in PVP K30, starch, cyanoacrylate, fibrin or polyurethane;
Described lubricant is the mixture of Pulvis Talci and magnesium stearate.
5. the preparation method of the Chinese medicinal tablet of control cardiovascular and cerebrovascular disease according to claim 1, is characterized in that, specifically comprise the following steps:
1) Rhizoma Chuanxiong, Radix Angelicae Sinensis are rendered to respectively in extraction pot, heat up heating, and reflux, extract, gets supernatant for subsequent use;
2) mixed with the water entering 3 times amount by Flos Carthami, heat up 70 ~ 80 DEG C of hot dipping secondaries after being heated to 100 ~ 105 DEG C, gets supernatant for subsequent use;
3) Rhizoma Chuanxiong, angelol extract merge, and reclaim ethanol, are concentrated into the extractum that relative density is 1.10, and after concentrated, extractum adds Radix Ginseng powder, mix homogeneously;
4) Rhizoma Chuanxiong, Radix Angelicae Sinensis, saffron aqueous solution are merged, in vacuum concentration pot, be concentrated into the extractum that relative density is 1.10, let cool, add ethanol and reach 60% to alcohol content, placement is spent the night, the supernatant after leaching precipitate with ethanol, reclaim ethanol, be concentrated into relative density about 1.35 ~ 1.38;
5) by after carrying out pulverizing, sieve operation mix homogeneously after step (3) mixed material and step (4) extract dry, add disintegrating agent, filler, wetting agent granulation, spraying dry, granulate, by Borneolum Syntheticum with spraying in dry granule after a small amount of anhydrous alcohol solution, add mix lubricant evenly after, tabletting.
6. the Chinese medicinal tablet of control cardiovascular and cerebrovascular disease according to claim 1 is for preventing and treating the purposes of cardiovascular and cerebrovascular disease.
7. purposes according to claim 6, is characterized in that: described cardiovascular and cerebrovascular disease is cerebral thrombosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410691999.9A CN104473989A (en) | 2014-11-26 | 2014-11-26 | Traditional Chinese medicine tablet for preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410691999.9A CN104473989A (en) | 2014-11-26 | 2014-11-26 | Traditional Chinese medicine tablet for preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104473989A true CN104473989A (en) | 2015-04-01 |
Family
ID=52748691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410691999.9A Pending CN104473989A (en) | 2014-11-26 | 2014-11-26 | Traditional Chinese medicine tablet for preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104473989A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108686151A (en) * | 2018-08-10 | 2018-10-23 | 刘晓东 | A kind of Chinese medicine that brain tonic restores |
| CN113413407A (en) * | 2021-05-28 | 2021-09-21 | 安徽九洲方圆制药有限公司 | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof |
-
2014
- 2014-11-26 CN CN201410691999.9A patent/CN104473989A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108686151A (en) * | 2018-08-10 | 2018-10-23 | 刘晓东 | A kind of Chinese medicine that brain tonic restores |
| CN113413407A (en) * | 2021-05-28 | 2021-09-21 | 安徽九洲方圆制药有限公司 | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104473989A (en) | Traditional Chinese medicine tablet for preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN103356980A (en) | Medicament for treating afterpains | |
| CN104906251A (en) | Traditional Chinese medicine compound combination with diabetes treating effect and preparation method and application thereof | |
| CN104857366A (en) | Preoperative intervention medicine composition for neurosurgery and application thereof | |
| CN101129972B (en) | Traditional Chinese medicine composition, preparation method and use of the same | |
| CN101632727B (en) | Application of Chinese medicinal composition in preparing medicament for treating pulmonary hypertension | |
| CN107890528B (en) | Traditional Chinese medicine composition for treating hyperuricemia and preparation method thereof | |
| CN100540017C (en) | A kind of Chinese medicine preparation for the treatment of angina pectoris and preparation method thereof | |
| CN101683406B (en) | Application of a traditional Chinese medicine composition in preparation of medicament for treating and preventing hypertension | |
| CN102940671B (en) | Medicine composition for treating diabetic foot | |
| CN104667183A (en) | Medicine preparation for treating damp-heat evil stagnation type pyogenic osteomyelitis and preparation method of medicine preparation | |
| CN102743456B (en) | The application of a kind of Chinese medicine composition in the medicine of preparation control delayed encephalopathy after acute carbon monoxide poisoning | |
| CN104027719A (en) | Traditional Chinese medicine compound composition capable of treating hypersplenism liver-depression and spleen-deficiency type diseases caused by infectious endocarditis and preparation method thereof | |
| CN103920042A (en) | Drug for treating heat invasion nutritive blood type virus meningitis, as well as preparation method thereof | |
| CN101612217B (en) | Application of Chinese medicinal composition in preparation of medicaments for treating central serous chorioretinopathy | |
| CN101161268B (en) | Pharmaceutical composition of red sage root and cattail pollen | |
| CN101391045B (en) | Traditional Chinese medicine compound preparation for treating migraine and general headache and preparation method thereof | |
| CN101176770B (en) | Pharmaceutical composition of folium ginkgo and cattail pollen | |
| CN101884660A (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases, and preparation method and application thereof | |
| CN107095977A (en) | A kind of medicament and its pharmaceutical formulation and preparation method with the malicious effect of fire row of dispelling | |
| CN106389702A (en) | Traditional Chinese medicine for recovering symptoms of gynecological and obstetric surgery and preparation method of traditional Chinese medicine | |
| CN103751314A (en) | Traditional Chinese medicine formula preparation for treating toothache and preparation method thereof | |
| CN119424526A (en) | A Chinese medicine composition, decoction and powder for treating embolism syndrome after TACE surgery for liver cancer | |
| CN101352488A (en) | Medicament composition for damp-heat type icterohepatitis and preparation method thereof | |
| CN119607103A (en) | Traditional Chinese medicine composition for promoting blood circulation and improving intelligence |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150401 |
|
| WD01 | Invention patent application deemed withdrawn after publication |